The gift will create the John M. O’Quinn Foundation Neurodegenerative Disorders Laboratory at Houston Methodist. Photo via houstonmethodist.org

Houston Methodist announced that it has received a $10 million gift from the The John M. O’Quinn Foundation to support research into neurological disorders, including Alzheimer’s disease, Parkinson’s disease and others.

The gift will create the John M. O’Quinn Foundation Neurodegenerative Disorders Laboratory at Houston Methodist, which will be led by Dr. Jun Li, who chairs the department of neurology at the Houston Methodist Neurological Institute. The NIH-backed researcher and his team will provide care, clinical trial opportunities and subspecialty programs through the lab, according to a release from Houston Methodist.

The funds will also be used to recruit neurodegenerative disorders specialists to lab by creating endowed research chairs, research fellowships and funding for pilot studies.

"Many neurodegenerative diseases are chronic and significantly impact the quality of life, causing pain, weakness, loss of ambulation and sensory loss,” Li says in a statement. “Our team is committed to working with patients to help make their lives better through treatment, and this generous gift fuels our determination to do even more and to help find therapies for these neurological diseases. This commitment from The John M. O’Quinn Foundation will support an interdisciplinary team of neurologists and neuroscientists to further explore treatment options.”

The O'Quinn Foundation has been a long-time supporter of the hospital group, according to Houston Methodist, and has had members of its organization suffer from neurodegenerative disorders.

"As our population continues to live longer, we believe it’s critical to help now, and we know Houston Methodist is best positioned with its renowned researchers and clinicians like Dr. Li to help those with neurodegenerative diseases to have a better quality of life, and ultimately, a treatment for these diseases that impact so many,” President and Executive Director of the foundation Robert C. Wilson III says in the statement.

Earlier this year, Houston Methodist also received a $1 million grant from Susan and William “Dub” Henning, Jr. to support Alzheimer’s research at the Nantz National Alzheimer Center at the hospital. It created the Susan and William Henning Jr. Neurodegenerative Research Endowment.

Meanwhile, over the summer, a Houston clinical-stage biotech that treats neurodegenerative diseases company went public. The company, Coya Therapeutics (Nasdaq: COYA), has developed a biologics therapy that prevents further spreading of neurodegenerative diseases by making regulatory T cells functional again and closed a $15.25 million IPO in January. Click here to learn more about the company's treatments for ALS and Alzheimer's.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Biosciences startup becomes Texas' first decacorn after latest funding

A Dallas-based biosciences startup whose backers include millionaire investors from Austin and Dallas has reached decacorn status — a valuation of at least $10 billion — after hauling in a series C funding round of $200 million, the company announced this month. Colossal Biosciences is reportedly the first Texas startup to rise to the decacorn level.

Colossal, which specializes in genetic engineering technology designed to bring back or protect various species, received the $200 million from TWG Global, an investment conglomerate led by billionaire investors Mark Walter and Thomas Tull. Walter is part owner of Major League Baseball’s Los Angeles Dodgers, and Tull is part owner of the NFL’s Pittsburgh Steelers.

Among the projects Colossal is tackling is the resurrection of three extinct animals — the dodo bird, Tasmanian tiger and woolly mammoth — through the use of DNA and genomics.

The latest round of funding values Colossal at $10.2 billion. Since launching in 2021, the startup has raised $435 million in venture capital.

In addition to Walter and Tull, Colossal’s investors include prominent video game developer Richard Garriott of Austin and private equity veteran Victor Vescov of Dallas. The two millionaires are known for their exploits as undersea explorers and tourist astronauts.

Aside from Colossal’s ties to Dallas and Austin, the startup has a Houston connection.

The company teamed up with Baylor College of Medicine researcher Paul Ling to develop a vaccine for elephant endotheliotropic herpesvirus (EEHV), the deadliest disease among young elephants. In partnership with the Houston Zoo, Ling’s lab at the Baylor College of Medicine has set up a research program that focuses on diagnosing and treating EEHV, and on coming up with a vaccine to protect elephants against the disease. Ling and the BCMe are members of the North American EEHV Advisory Group.

Colossal operates research labs Dallas, Boston and Melbourne, Australia.

“Colossal is the leading company working at the intersection of AI, computational biology, and genetic engineering for both de-extinction and species preservation,” Walter, CEO of TWG Globa, said in a news release. “Colossal has assembled a world-class team that has already driven, in a short period of time, significant technology innovations and impact in advancing conservation, which is a core value of TWG Global.”

Well-known genetics researcher George Church, co-founder of Colossal, calls the startup “a revolutionary genetics company making science fiction into science fact.”

“We are creating the technology to build de-extinction science and scale conservation biology,” he added, “particularly for endangered and at-risk species.”

Houston investment firm names tech exec as new partner

new hire

Houston tech executive Robert Kester has joined Houston-based Veriten, an energy-focused research, investment and strategy firm, as technology and innovation partner.

Kester most recently served as chief technology officer for emissions solutions at Honeywell Process Solutions, where he worked for five years. Honeywell International acquired Houston-based oil and gas technology company Rebellion Photonics, where Kester was co-founder and CEO, in 2019.

Honeywell Process Solutions shares offices in Houston with the global headquarters of Honeywell Performance Materials and Technologies. Honeywell, a Fortune 100 conglomerate, employs more than 850 people in Houston.

“We are thrilled to welcome Robert to the Veriten team,” founder and CEO Maynard Holt said in a statement, “and are confident that his technical expertise and skills will make a big contribution to Veriten’s partner and investor community. He will [oversee] every aspect of what we do, with the use case for AI in energy high on the 2025 priority list.”

Kester earned a doctoral degree in bioengineering from Rice University, a master’s degree in optical sciences from the University of Arizona and a bachelor’s degree in laser optical engineering technology from the Oregon Institute of Technology. He holds 25 patents and has more than 25 patents pending.

Veriten celebrated its third anniversary on January 10, the day that the hiring of Kester was announced. The startup launched with seven employees.

“With the addition of Dr. Kester, we are a 26-person team and are as enthusiastic as ever about improving the energy dialogue and researching the future paths for energy,” Holt added.

Kester spoke on the Houston Innovators Podcast in 2021. Listen here

.